Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Recurrence 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Hairy Cell 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 11fludarabine 8Dexamethasone 7pomalidomide 6pembrolizumab 6Rituximab 5obinutuzumab 4glofitamab 4daratumumab 4Immunotherapy, Adoptive 4Gemcitabine 4Bortezomib 4venetoclax 3selinexor 3fludarabine phosphate 3cemiplimab 3Temozolomide 3Nivolumab 3Melphalan 3Injections 3Etoposide 3zanubrutinib 2tocilizumab 2pirtobrutinib 2blinatumomab 2abemaciclib 2Sirolimus 2Oxaliplatin 2Mesna 2Lisaftoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × polatuzumab vedotin × 30 days × Clear all
NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Genmab

Phase 2 Recruiting
496 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡